A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114

Status:
Not yet recruiting

Trial end date:
2023-12-30

Target enrollment:

Participant gender:

A Phase 1 study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK114.

Phase 1

Akeso